Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TXN | P10599 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596802 | 0.85 | APOBEC3G (0.67) | APOBEC3GHTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL18787559 | 0.85 | APOBEC3G (0.43) | APOBEC3GSLC6A2SLC6A4TDP1 | |
| SCHEMBL18073782 | 0.82 | APOBEC3G (0.41) | APOBEC3GSLC6A2SLC6A4 | |
| SCHEMBL16710896 | 0.78 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL18762910 | 0.78 | APOBEC3G (0.41) | APOBEC3GHTR2AHTR2CHTR2BTXN | |
| SCHEMBL16710748 | 0.78 | FFAR1 (0.38) | APOBEC3GPTPN1 | |
| SCHEMBL18787558 | 0.77 | APOBEC3G (0.36) | APOBEC3GSLC6A2SLC6A4CETP | |
| SCHEMBL18762990 | 0.76 | S1PR1 (0.37) | APOBEC3GHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL16710820 | 0.75 | TDP1 (0.33) | APOBEC3GTDP1PTPN1 | |
| SCHEMBL16710762 | 0.75 | APOBEC3G (0.47) | APOBEC3GSLC6A2SLC6A4TDP1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190194655-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | BRADSHAW CURT W (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017100461-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | SOLSTICE BIOLOGICS, LTD. (IE) | 2017-06-15 | — | — | WO | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016094677-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS, LTD. (IE) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | APOBEC3G 234/4885HTR2A 4362/4885HTR2C 3555/4885 |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | APOBEC3G 81/4885HTR2A 3634/4885HTR2C 3883/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | APOBEC3G 234/4885HTR2A 4362/4885HTR2C 3555/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | APOBEC3G 81/4885HTR2A 3634/4885HTR2C 3883/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | APOBEC3G 312/4885HTR2A 4718/4885HTR2C 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.